Diagnostic Testing
Page 1 • 2 itemsGain critical insights into global diagnostic testing market trends, regulatory updates, and innovation impacting pharma BD and investment strategies.
FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
Guardant Health receives FDA approval for Guardant360 CDx liquid biopsy test as companion diagnostic for VEPPANU (vepdegestrant) in advanced breast cancer patients.
Labcorp Launches FDA-Approved PD-L1 Companion Diagnostic for KEYTRUDA Ovarian Cancer Treatment
Labcorp launches nationwide availability of FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic to identify ovarian cancer patients eligible for KEYTRUDA treatment.